Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate Formation.

Sadeque AJ, Palamar S, Usmani KA, Chen C, Cerny MA, Chen WG.

Drug Metab Dispos. 2016 Apr;44(4):570-5. doi: 10.1124/dmd.115.067397. Epub 2016 Jan 12.

PMID:
26758853
2.

Biopharmaceutics permeability classification of lorcaserin, a selective 5-hydroxytryptamine 2C agonist: method suitability and permeability class membership.

Chen C, Ma MG, Fullenwider CL, Chen WG, Sadeque AJ.

Mol Pharm. 2013 Dec 2;10(12):4739-45. doi: 10.1021/mp400468c. Epub 2013 Oct 29.

PMID:
24102111
3.

Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and duration.

Unett DJ, Gatlin J, Anthony TL, Buzard DJ, Chang S, Chen C, Chen X, Dang HT, Frazer J, Le MK, Sadeque AJ, Xing C, Gaidarov I.

J Pharmacol Exp Ther. 2013 Dec;347(3):645-59. doi: 10.1124/jpet.113.207670. Epub 2013 Sep 18.

PMID:
24049061
4.

Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist.

Usmani KA, Chen WG, Sadeque AJ.

Drug Metab Dispos. 2012 Apr;40(4):761-71. doi: 10.1124/dmd.111.043414. Epub 2012 Jan 20.

PMID:
22266842
5.

Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin.

Sadeque AJ, Usmani KA, Palamar S, Cerny MA, Chen WG.

Drug Metab Dispos. 2012 Apr;40(4):772-8. doi: 10.1124/dmd.111.043448. Epub 2012 Jan 18.

PMID:
22259019
6.

Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects.

Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJ.

Clin Pharmacol Ther. 2001 May;69(5):317-23.

PMID:
11371999
7.

Increased drug delivery to the brain by P-glycoprotein inhibition.

Sadeque AJ, Wandel C, He H, Shah S, Wood AJ.

Clin Pharmacol Ther. 2000 Sep;68(3):231-7.

PMID:
11014404
8.

Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.

Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE.

J Pharmacol Exp Ther. 1997 Nov;283(2):698-703.

PMID:
9353388
9.

Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization.

Haining RL, Hunter AP, Sadeque AJ, Philpot RM, Rettie AE.

Drug Metab Dispos. 1997 Jul;25(7):790-7.

PMID:
9224773
10.

Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase.

Rettie AE, Meier GP, Sadeque AJ.

Chem Biol Interact. 1995 Apr 28;96(1):3-15.

PMID:
7720102
11.
13.
14.

Ligand binding studies of engineered cytochrome P-450d wild type, proximal mutants, and distal mutants.

Shimizu T, Sadeque AJ, Sadeque GN, Hatano M, Fujii-Kuriyama Y.

Biochemistry. 1991 Feb 12;30(6):1490-6.

PMID:
1993167
15.

Electron spin resonance studies of wild-type and mutant cytochromes P-450d: effects of mutations at proximal, aromatic and distal sites on g values.

Sotokawa H, Shimizu T, Furuya H, Sadeque AJ, Hatano M, Ohba Y, Iwaizumi M, Fujii-Kuriyama Y.

Biochim Biophys Acta. 1990 Jan 19;1037(1):122-8.

PMID:
2153026
16.

Bindings of axial ligands to cytochrome P-450d mutants: a difference absorption spectral study.

Shimizu T, Sadeque AJ, Hatano M, Fujii-Kuriyama Y.

Biochim Biophys Acta. 1989 Apr 6;995(2):116-21.

PMID:
2649155

Supplemental Content

Loading ...
Support Center